Vaderis raises $152M Series B to launch Phase 3 trial of engasertib for hereditary hemorrhagic telangiectasia

Vaderis Therapeutics, a Swiss biotech, announced it has closed an oversubscribed $152 million Series B financing round.

The new capital will fund the initiation of a Phase 3 study, named HEROIC, evaluating the oral selective allosteric AKT1/2 inhibitor engasertib in patients with hereditary hemorrhagic telangiectasia (HHT), a rare vascular disorder.

HHT is characterized by arteriovenous malformations that cause nosebleeds, anemia and other complications. Engasertib targets AKT, a kinase involved in vascular growth, and earlier data published in the New England Journal of Medicine in November 2025 showed improvements across multiple disease measures.

If successful, engasertib could become the first approved therapy for HHT, addressing an unmet medical need.